Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
To explore the safety, tolerability, pharmacokinetics and efficacy of ABT-SLV187 in advanced
Parkinson's disease (PD) patients with severe motor complications. The complications of
medical devices for the naso-jejunum (NJ) infusion system of ABT-SLV187 will also be
investigated.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Abbott Japan Co.,Ltd
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa Silicon